Table 2 Costs estimated for a three-month period (one Markov model cycle) of each health state of the model, in Brazilian real (BRL) and percentage (%) by category in strategy 2 (XELOX plus bevacizumab)
Categories | First-line treatment (XELOX plus bevacizumab) | Second-line treatment (FOLFIRI) | Clinical Support | Death | ||||
|---|---|---|---|---|---|---|---|---|
R$ | % | R$ | % | R$ | % | R$ | % | |
Medications | 27,592.00 | 89.57 | 4327.80 | 33.33 | 0.00 | 0.00 | 0.00 | 0.00 |
Preparation (Pharmacy) | 120.08 | 0.39 | 270.18 | 2.08 | 0.00 | 0.00 | 0.00 | 0.00 |
Administration (Nursing) | 1006.40 | 3.27 | 6700.74 | 51.61 | 0.00 | 0.00 | 0.00 | 0.00 |
Laboratory tests | 367.00 | 1.19 | 409.08 | 3.15 | 265.48 | 5.28 | 0.00 | 0.00 |
Imaging tests | 1720.00 | 5.58 | 1276.20 | 9.83 | 0.00 | 0.00 | 0.00 | 0.00 |
Hospitalization | 0.00 | 0.00 | 0.00 | 0.00 | 4767.03 | 94.72 | 0.00 | 0.00 |
Total | 30,805.48 | 100.00 | 12,984.00 | 100.00 | 5032.51 | 100.00 | 0.00 | 0.00 |